MiNK Therapeutics (NASDAQ:INKT) Versus Voyager Therapeutics (NASDAQ:VYGR) Head to Head Comparison
MiNK Therapeutics (NASDAQ:INKT) Versus Voyager Therapeutics (NASDAQ:VYGR) Head to Head Comparison
Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
旅行者治疗公司(纳斯达克：VYGR-GET评级)和水貂治疗公司(纳斯达克：iNKT-GET评级)都是小盘医疗公司，但哪只股票更好？我们将根据两家公司的估值、收益、股息、风险、盈利能力、分析师推荐和机构持股情况对它们进行比较。
Earnings and Valuation
收益和估值
This table compares Voyager Therapeutics and MiNK Therapeutics' top-line revenue, earnings per share and valuation.
此表比较了Voyager治疗公司和水貂治疗公司的营收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Voyager Therapeutics | $37.42 million | 6.45 | -$71.20 million | ($0.46) | -13.59 |
| MiNK Therapeutics | $690,000.00 | 112.62 | -$30.21 million | ($0.78) | -2.95 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 旅行者治疗公司 | 3,742万美元 | 6.45 | -7,120万美元 | ($0.46) | -13.59 |
| 水貂治疗公司 | $690,000.00 | 112.62 | -3021万美元 | ($0.78) | -2.95 |
MiNK Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.
水貂治疗公司的收入低于旅行者治疗公司，但收益高于旅行者治疗公司。Voyager治疗公司的市盈率低于水貂治疗公司，这表明它目前是两只股票中更负担得起的一只。
Institutional & Insider Ownership
机构与内部人持股
Volatility & Risk
波动性与风险
Voyager Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500.
Voyager Treateutics的贝塔系数为0.96，表明其股价的波动性比标准普尔500指数低4%。相比之下，水貂治疗公司的贝塔系数为-0.63，这表明其股价的波动性比标准普尔500指数低163%。
Profitability
盈利能力
This table compares Voyager Therapeutics and MiNK Therapeutics' net margins, return on equity and return on assets.
此表比较了Voyager治疗公司和水貂治疗公司的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Voyager Therapeutics | -24.21% | -21.97% | -8.65% |
| MiNK Therapeutics | N/A | -168.94% | -78.30% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 旅行者治疗公司 | -24.21% | -21.97% | -8.65% |
| 水貂治疗公司 | 不适用 | -168.94% | -78.30% |
Analyst Recommendations
分析师建议
This is a breakdown of recent recommendations for Voyager Therapeutics and MiNK Therapeutics, as reported by MarketBeat.com.
据MarketBeat.com报道，这是Voyager治疗公司和水貂治疗公司最近推荐的细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Voyager Therapeutics | 0 | 0 | 0 | 0 | N/A |
| MiNK Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 旅行者治疗公司 | 0 | 0 | 0 | 0 | 不适用 |
| 水貂治疗公司 | 0 | 0 | 2 | 0 | 3.00 |
Voyager Therapeutics currently has a consensus target price of $6.00, indicating a potential downside of 4.00%. MiNK Therapeutics has a consensus target price of $7.00, indicating a potential upside of 204.35%. Given MiNK Therapeutics' higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Voyager Therapeutics.
Voyager治疗公司目前的共识目标价为6.00美元，这表明潜在的下行幅度为4.00%。水貂治疗公司的共识目标价为7美元，表明潜在上涨204.35%。考虑到水貂治疗公司更有可能的上行空间，分析师们显然认为水貂治疗公司比旅行者治疗公司更有利。
Summary
摘要
Voyager Therapeutics beats MiNK Therapeutics on 7 of the 13 factors compared between the two stocks.
Voyager治疗公司在两只股票之间的13个因素中有7个击败了水貂治疗公司。
About Voyager Therapeutics
关于旅行者治疗公司
(Get Rating)
(获取评级)
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Voyager治疗公司是一家基因治疗公司，专注于治疗和下一代平台技术的开发。该公司的主要临床候选药物是VY-AADC，它正在进行治疗帕金森病的开放标签第一阶段临床试验。它的临床前计划包括用于治疗肌萎缩侧索硬化症的VY-SOD102；用于亨廷顿病的VY-HTT01；用于Friedreich共济失调的VY-FXN01；以及用于治疗包括阿尔茨海默病、进行性核上性瘫痪和额颞部痴呆以及脊髓性肌萎缩症在内的各种疾病的Tau计划。该公司与辉瑞的Neurocrine生物科学公司和A.G.诺华制药公司就腺相关病毒基因治疗产品的研究、开发和商业化达成合作和许可协议。Voyager治疗公司成立于2013年，总部设在马萨诸塞州剑桥市。
About MiNK Therapeutics
关于水貂治疗公司
(Get Rating)
(获取评级)
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
明克治疗公司是一家临床阶段的生物制药公司，致力于同种异体、现成、不变的自然杀伤T(INKT)细胞疗法的发现、开发和商业化，以治疗癌症和其他免疫介导性疾病。它的候选产品是AGENT-797，这是一种现成的同种异体药物，用于iNKT细胞治疗和治疗各种骨髓瘤疾病，目前处于第一阶段临床试验。该公司前身为AgenTus治疗公司。水貂治疗公司成立于2017年，总部设在纽约。明克治疗公司是Agenus公司的子公司。
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受旅行者治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收Voyager Treeutics和相关公司的最新新闻和分析师评级的每日摘要。